芪参益气活血胶囊对气虚血瘀型冠心病并前临床心力衰竭患者心室重构及神经内分泌的影响

Effects of Qishen Yiqi Huoxue Capsules on Ventricular Remodeling and Neuroendocrine in Patients with Coronary Heart Disease with Qi Deficiency and Blood Stasis Type Complicated with Preclinical Heart Failure

目的探讨芪参益气活血胶囊治疗气虚血瘀型冠心病并前临床心力衰竭患者的效果.方法选取本院2019年2月—2021年2月收治的气虚血瘀型冠心病并前临床心力衰竭患者84例为研究对象,采用随机数字表法将其分为对照组(42例)与观察组(42例).对照组采用基础药物治疗及心衰B阶段治疗,观察组在此基础上加用芪参益气活血胶囊治疗,4周为1个疗程.持续观察6个月后,对比两组的左室舒张末期内径(LVEDD)、左室收缩末期内径(LVEDS)、室间隔厚度(IVST)、左室射血分数(LVEF)、左室质量指数(LVMI)、N末端脑钠肽前体(NT-proBNP)、血管紧张素(AngⅡ)、醛固酮(ALD).结果治疗后6个月,观察组的LVEDD、LVEDS、LVMI均低于对照组,LVEF高于对照组,组间差异有统计学意义(P<0.05).治疗后6个月,观察组的NT-proBNP水平低于对照组,差异有统计学意义(P<0.05);两组的AngⅡ、ALD水平比较,组间差异无统计学意义(P>0.05).治疗期间两组均未发生严重不良反应.结论采用芪参益气活血胶囊治疗气虚血瘀型冠心病并前临床心力衰竭,能够抑制心室重构,利于延缓心衰进展.

Objective To investigate the therapeutic effect of Qishen Yiqi Huoxue Capsules on the treatment of Qi deficiency and blood stasis coronary heart disease combined with preclinical heart failure.Methods A total of 84 patients with Qi deficiency and blood stasis coronary heart disease combined with preclinical heart failure admitted to our hospital from February 2019 to February 2021 were selected as the subjects,and the patients were divided into a control group(42 cases)and an observation group(42 cases)by random number table method.The control group was treated with conventional western medicine,and the observation group was additionally treated with Qishen Yiqi Huoxue Capsules on this basis.Both groups were treated for 4 weeks as a course.After 6 months of continuous observation,the left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVEDS),interventricular septal thickness(IVST),left ventricular ejection fraction(LVEF),left ventricular mass index(LVMI)and N-terminal brain natriuretic peptide precursor(NT-probNP),angiotensin(AngⅡ),aldosterone(ALD)were compared between two groups.Results 6 months after treatment,the LVEDD,LVEDS and LVMI in the observation group were lower than those in the control group,while LVEF was higher than that in the control group,the differences between the groups were statistically significant(P<0.05).6 months after treatment,the level of NT-probNP in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05);while there were no significant differences in AngⅡand ALD levels between the two groups(P>0.05).No serious adverse reactions occurred in the two groups during treatment.Conclusion Qishen Yiqi Huoxue Capsules can inhibit ventricular remodeling and delay the progression of heart failure in the treatment of Qi deficiency and blood stasis coronary heart disease combined with preclinical heart failure.